Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Vranckx

Showing results (261-270 of 305) with videos related to

Pageof 31
Sort By:
Circulation|August 30, 2021
Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled TrialPieter C Smits, Enrico Frigoli, Jan Tijssen, et al.
The American Journal of Cardiology|October 26, 2019
Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)Chun Chin Chang, Ernest Spitzer, Ply Chichareon, et al.
Journal of the American College of Cardiology|September 22, 2022
Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding RiskPieter C Smits, Enrico Frigoli, Pascal Vranckx, et al.
Journal of the American College of Cardiology|May 23, 2017
Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIXGiuseppe Andò, Bernardo Cortese, Filippo Russo, et al.
BMJ (Clinical Research Ed.)|June 17, 2021
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trialsMarco Valgimigli, Felice Gragnano, Mattia Branca, et al.
Journal of the American College of Cardiology|February 8, 2023
P2Y<sub>12</sub> Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary InterventionsFelice Gragnano, Roxana Mehran, Mattia Branca, et al.
European Heart Journal|July 12, 2018
Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC)Marco Valgimigli, Hector M Garcia-Garcia, Bernard Vrijens, et al.
Circulation. Cardiovascular Quality and Outcomes|February 4, 2021
Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSYSergio Leonardi, Mattia Branca, Anna Franzone, et al.
International Journal of Cardiology|March 9, 2019
Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS studyPly Chichareon, Rodrigo Modolo, David van Klaveren, et al.
BMJ Open|March 11, 2019
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)Sergio Leonardi, Anna Franzone, Raffaele Piccolo, et al.
Pageof 31

Showing results (261-270 of 305) with videos related to

Sort By:
Pageof 31
Circulation|August 30, 2021
Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled TrialPieter C Smits, Enrico Frigoli, Jan Tijssen, et al.
The American Journal of Cardiology|October 26, 2019
Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)Chun Chin Chang, Ernest Spitzer, Ply Chichareon, et al.
Journal of the American College of Cardiology|September 22, 2022
Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding RiskPieter C Smits, Enrico Frigoli, Pascal Vranckx, et al.
Journal of the American College of Cardiology|May 23, 2017
Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIXGiuseppe Andò, Bernardo Cortese, Filippo Russo, et al.
BMJ (Clinical Research Ed.)|June 17, 2021
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trialsMarco Valgimigli, Felice Gragnano, Mattia Branca, et al.
Journal of the American College of Cardiology|February 8, 2023
P2Y<sub>12</sub> Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary InterventionsFelice Gragnano, Roxana Mehran, Mattia Branca, et al.
European Heart Journal|July 12, 2018
Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC)Marco Valgimigli, Hector M Garcia-Garcia, Bernard Vrijens, et al.
Circulation. Cardiovascular Quality and Outcomes|February 4, 2021
Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSYSergio Leonardi, Mattia Branca, Anna Franzone, et al.
International Journal of Cardiology|March 9, 2019
Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS studyPly Chichareon, Rodrigo Modolo, David van Klaveren, et al.
BMJ Open|March 11, 2019
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)Sergio Leonardi, Anna Franzone, Raffaele Piccolo, et al.
Pageof 31